“Positive pharmacokinetic data” sparked much speculation in a Canada-listed biotech stock Thursday. Here’s some small stocks making big moves on Thursday, September 6, 2018 (as of 4 pm EST):
iCo Therapeutics (TSXV:ICO), a biotech stock, jumped 39% to $0.125 on Thursday after announcing what it called “additional positive pharmacokinetic data” from its recent Phase 1 study of its Oral Amphotericin B (Oral Amp B) candidate, reporting a median AUC0-inf of 2029 hr*ng/mL at the 400 mg dose of Oral Amphotericin B, representing an approximate doubling of the critical AUC0-inf measure at an increased dose.
As well, shares of Cypress Development Corp. (TSXV:CYP) slipped 19% to $0.325 as the lithium junior revealed results from a Preliminary Economic Assessment (PEA) of its Clayton Valley Lithium Project in Nevada. Highlights included an estimated Net Present Value of US$1.45 billion, at an 8% discount rate, and a 32.7% internal rate of return on after-tax cash flow.
Cornerstone Capital Resources Inc. (TSXV:CGP), meanwhile, reported that its Board of Directors has decided not to proceed with the previously-announced plan of arrangement at this time, which would have involved a spin-off transaction transferring its non-Cascabel assets to a newly-created company. Cornerstone Capital stock moved up 50% to $0.27 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
iCo Therapeutics (TSXV:ICO), a biotech stock, jumped 39% to $0.125 on Thursday after announcing what it called “additional positive pharmacokinetic data” from its recent Phase 1 study of its Oral Amphotericin B (Oral Amp B) candidate, reporting a median AUC0-inf of 2029 hr*ng/mL at the 400 mg dose of Oral Amphotericin B, representing an approximate doubling of the critical AUC0-inf measure at an increased dose.
